Novel and reported pathogenic variants in exon 11 of BRCA2 gene in a cohort of Sri Lankan young breast cancer patients
- 226 Downloads
Women with breast carcinoma diagnosed before 40 years of age with a strong familial risk have a greater prevalence of germline BRCA1 or BRCA2 variants than late onset breast cancer. Previously germline variants in BRCA1 and BRCA2 genes were characterized in a cohort of Sri Lankan breast cancer patients unselected for age of onset. This study focused on young breast cancer patients who were screened for previously identified hotspot regions in BRCA2 gene. A total of 48 young breast cancer patients with family history of cancer and 25 healthy controls were studied. Direct sequencing was used to detect pathogenic and other sequence variants in the hotspot regions of BRCA2 gene. Thirty-six sequence variants including seven pathogenic (c.2411_2412delAA/p.Glu804Valfs*2, c.2500_2501insG/p.Leu834Cysfs*4, c.3881T>G/p.Leu1294*, c.4768A>T/p.Lys1590*, c.5645C>G/p.Ser1882*, c.5747delC/p.His1916Phefs*3, c.6728C>T/p.Ser2243Phe) and two likely pathogenic (c.1922C>T and c.3378A>T) variants, two intronic variants of unknown significance (c.1910-74T>C, c.1910-51G>T), two variants of uncertain significance (c.2324C>T c.5104C>T) and 23 benign variants were detected. Among them, seven were novel (pathogenic 5 and likely pathogenic 2). Prevalence of pathogenic and likely pathogenic variants in the hotspots regions of BRCA2 was 23 and 6.3 % respectively in this cohort. This justifies BRCA2 variant testing in young breast cancer patients with family history of cancer in Sri Lanka.
KeywordsBRCA2 Hotspot regions Young breast cancer patients Sri Lanka
The authors are very grateful to the Director and staff of the National Cancer Institute, Maharagama, Sri Lanka for their cooperation and all young patients who agreed to participate in this study, Dr. Vathsal Bandaranayake and Dr. Niroshan Atulugama for assistance with sample collection from breast cancer clinic.
This study was funded by National Science Foundation, Sri Lanka (Grant Number RG/2014/BT/04).
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
- 4.Armes JE, Egan AJM, Southey MC, Dite GS, McCredie MRE, Giles GG, Hopper JL, Venter DJ (1998) The histologic phenotypes of breast carcinoma occurring before Age 40 years in women with and without BRCA1 or BRCA2 germline mutations: a population-based study. Cancer 83(11):2335–2345CrossRefPubMedGoogle Scholar
- 7.Metcalfe K, Gershman S, Lynch HT, Ghadirian P, Tung N, Kim-Sing C, Olopade OI, Domchek S, McLennan J, Eisen A, Foulkes WD, Rosen B, Sun P, Narod SA (2011) Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. Br J Cancer 104(9):1384–1392. doi: 10.1038/bjc.2011.120 CrossRefPubMedPubMedCentralGoogle Scholar
- 8.Cancer Registry (2010) National Cancer Control Programme, Government Cancer Institute, Cancer Incidence Data, MaharagamaGoogle Scholar
- 9.Cancer Registry (2009) National Cancer Control Programme, Government Cancer Institute: Cancer Incidence Data, MaharagamaGoogle Scholar
- 11.De Silva S, Tennekoon KH, Karunanayake EH, De Silva W, Amarasinghe I, Angunawala P (2011) Novel sequence variants and common recurrent polymorphisms of BRCA2 in Sri Lankan breast cancer patients and a family with BRCA1 mutations. Exp Ther Med 2 (6):1163–1170Google Scholar
- 12.De Silva W, Karunanayake EH, Tennekoon KH, Allen M, Amarasinghe I, Angunawala P, Ziard MH (2008) Novel sequence variants and a high frequency of recurrent polymorphisms in BRCA1 gene in Sri Lankan breast cancer patients and at risk individuals. BMC Cancer 8:214. doi: 10.1186/1471-2407-8-214 CrossRefPubMedPubMedCentralGoogle Scholar
- 13.Kwong A, Shin VY, Ho JC, Kang E, Nakamura S, Teo SH, Lee AS, Sng JH, Ginsburg OM, Kurian AW, Weitzel JN, Siu MT, Law FB, Chan TL, Narod SA, Ford JM, Ma ES, Kim SW (2016) Comprehensive spectrum of BRCA1 and BRCA2 deleterious mutations in breast cancer in Asian countries. J Med Genet 53(1):15–23. doi: 10.1136/jmedgenet-2015-103132 CrossRefPubMedGoogle Scholar
- 14.Breast Cancer Information Core [BIC] (2016). http://research.nhgri.nih.gov/bic/.
- 16.Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, Voelkerding K, Rehm HL (2015) ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 17(5):405–424. doi: 10.1038/gim.2015.30 CrossRefPubMedPubMedCentralGoogle Scholar
- 17.Rebbeck TR, Mitra N, Wan F, Sinilnikova OM, Healey S, McGuffog L, Mazoyer S, Chenevix-Trench G, Easton DF, Antoniou AC, Nathanson KL and the CIMBA Consortium (2015) Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. JAMA 313(13):1347–1361. doi: 10.1001/jama.2014.5985 CrossRefPubMedPubMedCentralGoogle Scholar
- 19.Wong ES, Shekar S, Chan CH, Hong LZ, Poon SY, Silla T, Lin C, Kumar V, Davila S, Voorhoeve M, Thike AA, Ho GH, Yap YS, Tan PH, Tan MH, Ang P, Lee AS (2015) Predictive factors for BRCA1 and BRCA2 genetic testing in an Asian clinic-based population. PLoS ONE 10(7):e0134408. doi: 10.1371/journal.pone.0134408 CrossRefPubMedPubMedCentralGoogle Scholar
- 20.Caputo S, Benboudjema L, Sinilnikova O, Rouleau E, Béroud C, Lidereau R; French BRCA GGC Consortium (2012) Description and analysis of genetic variants in French hereditary breast and ovarian cancer families recorded in the UMD-BRCA1/BRCA2 databases. Nucleic Acids Res 40(Database issue):D992–1002. doi: 10.1093/nar/gkr1160 CrossRefPubMedGoogle Scholar
- 21.Pohlreich P, Zikan M, Stribrna J, Kleibl Z, Janatova M, Kotlas J, Zidovska J, Novotny J, Petruzelka L, Szabo C, Matous B (2005) High proportion of recurrent germline mutations in the BRCA1 gene in breast and ovarian cancer patients from the Prague area. Breast Cancer Res 7(5):R728–R736CrossRefPubMedPubMedCentralGoogle Scholar
- 22.Kim H, Cho DY, Choi DH, Choi SY, Shin I, Park W, Huh SJ, Han SH, Lee MH, Ahn SH, Son BH, Kim SW, Korean Breast Cancer Study Group, Haffty BG (2012) Characteristics and spectrum of BRCA1 and BRCA2 mutations in 3922 Korean patients with breast and ovarian cancer. Breast Cancer Res Treat 134(3):1315–1326. doi: 10.1007/s10549-012-2159-5 CrossRefPubMedGoogle Scholar
- 23.Toh GT, Kang P, Lee SS, Lee DS, Lee SY, Selamat S, Mohd Taib NA, Yoon SY, Yip CH, Teo SH (2008) BRCA1 and BRCA2 germline mutations in Malaysian women with early-onset breast cancer without a family history. PLoS ONE 3(4):e2024. doi: 10.1371/journal.pone.0002024 CrossRefPubMedPubMedCentralGoogle Scholar